Email Alerts Required fields denoted by an asterisk (). Alert type Quote SEC Filing Event News Weekly Summary Email Leave this field blank
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Innovation is the Best Medicine: How CEO Shane Schaffer and Cingulate Developed “Precision Timed Release,” a New Drug Delivery Platform for ADHD
